Adjuvant Radiotherapy in Patients With Early Endometrial Cancer
- Conditions
- Endometrial CancerRadiotherapyPathology
- Interventions
- Radiation: vaginal brachytherapy/pelvic external beam radiotherapy
- Registration Number
- NCT04956601
- Lead Sponsor
- Peking University Third Hospital
- Brief Summary
To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.
- Detailed Description
After being informed the study and potential risk,all patients giving written informed consent will be undergo a 1-week screening period determine eligibility for study entry. At week 0, patients who meet the eligibility will be randomized in a 1:1 ratio to vaginal brachytherapy or pelvic external beam radiotherapy. After treatment, patients were followed up regularly.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- Female
- Target Recruitment
- 480
- Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type;
- Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion;
- Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional;
- ECOG score is 0-2;
- The interval time between surgery and radiotherapy is no more than 8 weeks;
- The routine blood examination was normal;
- Compliance is good and informed consent is voluntarily signed.
- The patients receive chemotherapy;
- History of previous malignant disease;
- Previous diagnosis of Crohn's disease or ulcerative colitis.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description VBT vaginal brachytherapy/pelvic external beam radiotherapy CT image guided high-dose-rate vaginal brachytherapy, 30Gy/6f, 2f/w. EBRT vaginal brachytherapy/pelvic external beam radiotherapy Pelvic external beam radiotherapy,IMRT/VAMT,IGRT suggested,DT 45Gy/25f.
- Primary Outcome Measures
Name Time Method DFS 5-year disease-free survival from being received treatment
- Secondary Outcome Measures
Name Time Method Failure mode 5-year vaginal recurrences; pelvic recurrence; distant metastases
OS 5-year Overall survival from being received treatment
Toxicities 5-year from being received treatment
Trial Locations
- Locations (1)
Peking University 3rd Hospital
🇨🇳Beijing, Beijng, China